Company Overview - CalciMedica Inc. is a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses [3] - The company's lead product candidate, Auxora™, has shown positive and consistent clinical results in multiple completed efficacy clinical trials [3] Clinical Trials and Developments - CalciMedica has announced data for a Phase 2b trial (CARPO – NCT04681066) in patients with acute pancreatitis (AP) and accompanying systemic inflammatory response syndrome (SIRS) [3] - The company completed a Phase 2 trial (CARDEA – NCT04345614) in patients with COVID pneumonia [3] - Currently, CalciMedica is conducting a Phase 2 trial (KOURAGE – NCT06374797) in patients with acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF), with data expected around the end of 2025 [3] - The company is also supporting an ongoing investigator-initiated Phase 1/2 trial (CRSPA – NCT04195347) in pediatric patients with asparaginase-induced pancreatic toxicity (AIPT), with an update expected in the second half of 2025 [3] Upcoming Events - Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica, will present at the Jones Healthcare and Technology Innovation Conference on April 9, 2025, at 11:00 a.m. PT [1] - A live webcast of the presentation will be available on CalciMedica's IR website, with a replay archived for 90 days [2]
CalciMedica to Participate in the Jones Healthcare and Technology Innovation Conference